Overhauling the breast cancer overview: Are subsets subversive?

Lancet Oncology

Volumn 3, Issue 9, 2002, Pages 525-526

  Coates, Alan S ^a   Goldhirsch, Aron ^b,c   Gelber, Richard D ^d  

^a CANCER COUNCIL AUSTRALIA   (Australia)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

BREAST CANCER; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; METASTASIS; NOTE; POSTMENOPAUSE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0036711592     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00842-2     Document Type: Letter

References (6)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Polychemotherapy for early breast cancer: An overview of the randomised trials
3. Patient preferences for adjuvant chemotherapy of early breast cancer: How much benefit is needed?
4. Subsets within the chemotherapy overview
5. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial
6. Polychemotherapy for early breast cancer: An overview of the randomised clinical trials with quality-adjusted survival analysis